AI Verdict
ROKU has stronger fundamentals based on our AI analysis.
ROKU vs RNTX Fundamental Comparison
| Metric | ROKU | RNTX |
|---|---|---|
| Revenue | $4.7B | $0.0 |
| Net Income | $88.4M | $-49.9M |
| Net Margin | 1.9% | N/A |
| ROE | 3.3% | -294.8% |
| ROA | 2.0% | -206.4% |
| Current Ratio | 2.75x | 0.70x |
| Debt/Equity | 0.00x | 0.00x |
| EPS | $0.59 | $-1.96 |
Green = Better metric | Red = Weaker metric
You Might Also Compare
ROKU vs RNTX: Frequently Asked Questions
Is ROKU or RNTX a better buy in 2026?
Based on dual AI fundamental analysis (Claude and ChatGPT), ROKU has stronger fundamentals. ROKU is rated HOLD (72% confidence) while RNTX is rated STRONG SELL (95% confidence). This is not investment advice.
How does ROKU compare to RNTX fundamentally?
ROKU, INC has ROE of 3.3% vs Rein Therapeutics, Inc.'s -294.8%. Net margins are 1.9% vs N/A respectively.
Which stock pays higher dividends, ROKU or RNTX?
ROKU has a dividend yield of N/A or no dividend while RNTX has N/A or no dividend. Check individual stock pages for detailed dividend history and payout ratios.
Should I invest in ROKU or RNTX for long term?
For long-term investing, consider that ROKU has HOLD rating with 72% confidence, while RNTX has STRONG SELL rating with 95% confidence. Higher confidence indicates more consistent fundamentals from SEC filings. This is not investment advice - always do your own research.
What do the AI models say about ROKU vs RNTX?
Our dual AI system (Claude by Anthropic and ChatGPT by OpenAI) analyzes SEC 10-K and 10-Q filings independently. For ROKU vs RNTX, the AI consensus favors ROKU based on fundamental metrics including revenue growth, profitability, ROE, and balance sheet strength.